Lynda Seminara | Authors


PI3K Inhibition May Fuel Cancer Rather Than Fight It

July 06, 2015

A study, by M. Cecilia Cano, PhD, et al at the Wistar Institute, Philadelphia, has shown that monotherapy treatment with PI3K inhibitors may worsen a patient’s cancer by causing more aggressive tumor cell behavior and increasing the likelihood of metastases to other organs.

Targeted Treatments Dominate Spending Landscape in Oncology

May 21, 2015

A study published in the Journal of Clinical Oncology, May 18, 2015, details payer cost and use, as well as out-of-pocket (OOP) spending, for privately insured nonelderly patients receiving oral or intravenous (IV) chemotherapy for the treatment of cancer.